GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism

Proceedings of the National Academy of Sciences of the United States of America

Volumn 106, Issue 4, 2009, Pages 1285-1290

  Li, Yazhou ^a   Perry, TracyAnn ^a   Kindy, Mark S ^b,c   Harvey, Brandon K ^d   Tweedie, David ^a   Holloway, Harold W ^a   Powers, Kathleen ^d   Shen, Hui ^d   Egan, Josephine M ^a   Sambamurti, Kumar ^b   Brossi, Arnold ^e   Lahiri, Debomoy K ^f   Mattson, Mark P ^a   Hoffer, Barry J ^d   Wang, Yun ^d   Greig, Nigel H ^a  

^a NATIONAL INSTITUTE ON AGING   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c Neurological Testing Services   (United States)

^d NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^e UNIVERSITY OF NORTH CAROLINA   (United States)

^f INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Diabetes; Exendin 4; Neurodegeneration; Neuroprotection; Stroke

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; DOPAMINE; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; OXIDOPAMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; BRAIN DAMAGE; BRAIN NERVE CELL; CELL DEATH; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; GENE EXPRESSION; HUMAN; HUMAN CELL; HYPOXIA; MALE; MOTOR PERFORMANCE; NERVE DEGENERATION; NEUROPROTECTION; NONHUMAN; OCCLUSIVE CEREBROVASCULAR DISEASE; PARKINSON DISEASE; PRIORITY JOURNAL; RAT;

MUS; RODENTIA;

EID: 59049087723     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0806720106     Document Type: Article

References (45)

1. Sicree R, Shaw J, Zimmet P (2006) in Diabetes Atlas, ed Gan D (International Diabetes Federation, Brussels) 3rd Ed, pp 15-103.
2. Hollander M, et al. (2003) Incidence, risk, and case fatality of first ever stroke in the elderly population: The Rotterdam Study. J Neurol Neurosurg Psychiatry 74:317-321.
3. Ott A, et al. (1999) Diabetes mellitus and the risk of dementia: The Rotterdam Study. Neurology 53:1937-1942.
4. Arvanitakis Z, Wilson RS, Bienias JL, Evans DA, Bennett DA (2004) Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function. Arch Neurol 61:661-666.
5. Craft S, Watson GS (2004) Insulin and neurodegenerative disease: Shared and specific mechanisms. Lancet 3:169-178.
6. Perry T, Greig NH (2003) The glucagon-like peptides: A double-edged therapeutic sword? Trends Pharmacol Sci 24:377-383.
7. Baggio LL, Drucker DJ (2007) Biology of incretins: GLP-1 and GIP. Gastroenterology 132:2131-2157.
8. Li Y, et al. (2003) Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis. J Biol Chem 278:471-478.
9. Goke R, Larsen PJ, Mikkelsen JD, Sheikh SP (1995) Distribution of GLP-1 binding sites in the rat brain: Evidence that exendin-4 is a ligand of brain GLP-1 binding sites. Eur J Neurosci 7:2294-2300.
10. Satoh F, et al. (2000) Characterization of human and rat glucagon-like peptide-1 receptors in the neurointermediate lobe: Lack of coupling to either stimulation or inhibition of adenylyl cyclase. Endocrinology 141:1301-1309.
11. Banks WA, During MJ, Niehoff ML (2004) Brain uptake of the glucagon-like peptide-1 antagonist exendin(9-39) after intranasal administration. J Pharmacol Exp Ther 309:469-475.
12. Turton MD, et al. (1996) A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 379:69-72.
13. Perry T, et al. (2002) A novel neurotrophic property of glucagon-like peptide 1: A promoter of nerve growth factor-mediated differentiation in PC12 cells. J Pharmacol Exp Ther 300:958-966.
14. Perry T, et al. (2002) Protection and reversal of excitotoxic damage by glucagon-like peptide-1 and exendin-4. J Pharmacol Exp Ther 302:1-8.
15. Perry T, et al. (2003) Glucagon-like peptide-1 decreases endogenous Aβ levels and protects hippocampal neurons from death induced by Aβ and iron. J Neurosci Res 72:603-612.
16. Javitch JA, D'Amato RJ, Strittmatter SM, Snyder SH (1985) Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: Uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity. Proc Natl Acad Sci U S A 82:2173-2177.
17. Jeerakathil T, Johnson JA, Simpson SH, Majumdar SR (2007) Short-term risk for stroke is doubled in persons with newly treated type 2 diabetes compared with persons without diabetes: A population-based cohort study. Stroke 38:1739-1743.
18. Hu G, Jousilahti P, Bidel S, Antikainen R, Tuomilehto J (2007) Type 2 diabetes and the risk of Parkinson's disease. Diabetes Care 30:842-847.
19. Mattson MP (2007) Calcium and neurodegeneration. Aging Cell 6:337-350.
20. Duan W, et al. (2002) p53 inhibitors preserve dopamine neurons and motor function in experimental parkinsonism. Ann Neurol 52:597-606.
21. Tatton NA (2000) Increased caspase 3 and Bax immunoreactivity accompany nuclear GAPDH translocation and neuronal apoptosis in Parkinson's disease. Exp Neurol 166:29-43.
22. Bredesen DE, Rao RV, Mehlen P (2006) Cell death in the nervous system. Nature 443:796-802.
23. Lee SC, Pervaiz S (2007) Apoptosis in the pathophysiology of diabetes mellitus. Int J Biochem Cell Biol 39:497-504.
24. Rydel RE, Greene LA (1988) cAMP analogs promote survival and neurite outgrowth in cultures of rat sympathetic and sensory neurons independently of nerve growth factor. Proc Natl Acad Sci U S A 85:1257-1261.
25. Mena MA, Caserejos MJ, Bonin A, Ramos JA, Yebenes JG (1995) Effects of dibutyryl cyclic AMP and retinoic acid on the differentiation of dopamine neurons: prevention of cell death by dibutyryl cyclic AMP. J Neurochem 65:2612-2620.
26. Kew JN, Smith DW, Sofroniew MV (1996) Nerve growth factor withdrawal induces the apoptotic death of developing septal cholinergic neurons in vitro: protection by cyclic AMP analogue and high potassium. Neuroscience 70:329-339.
27. D'Mello SR, Galli C, Ciotti T, Calissano P (1993) Induction of apoptosis in cerebellar granule neurons by low potassium: Inhibition of death by insulin-like growth factor I and cAMP. Proc Natl Acad Sci U S A 90:10989-10993.
28. Villalba M, Bockaert J, Journot L (1997) Pituitary adenylate cyclase-activating polypeptide (PACAP-38) protects cerebellar granule neurons from apoptosis by activating the mitogen-activated protein kinase (MAP kinase) pathway. J Neurosci 17:83-90.
29. Hanson MG, Shen S, Wiemelt AP, McMorris F, Barres BA (1998) Cyclic AMP elevation is sufficient to promote the survival of spinal motor neurons in vitro. J Neurosci 18:7361-7371.
30. Yamamoto H, et al. (2003) Glucagon-like peptide-1-responsive catecholamine neurons in the area postrema link peripheral glucagon-like peptide-1 with central autonomic control sites. J Neurosci 23:2939-2946.
31. Lazaroff M, Patankar S, Yoon SO, Chikaraishi DM (1995) The cyclic AMP response element directs tyrosine hydroxylase expression in catecholaminergic central and peripheral nervous system cell lines from transgenic mice. J Biol Chem 270:21579-21589.
32. During MJ, et al. (2003) Glucagon-like peptide-1 receptor is involved in learning and neuroprotection. Nat Med 9:1173-1179.
33. Perry T, Greig NH (2005) Enhancing central nervous system endogenous GLP-1 receptor pathways for intervention in Alzheimer's disease. Curr Alzheimer Res 2:377-385.
34. Calara F, et al. (2005) A randomized, open-label, crossover study examining the effect of injection site on bioavailability of exenatide (synthetic Exendin-4). Clin Ther 27:210-215.
35. Perry T, et al. (2007) Evidence of GLP-1-mediated neuroprotection in an animal model of pyridoxine-induced peripheral sensory neuropathy. Exp Neurol 203:293-301.
36. Li Y, Chopp M, Powers C, Jiang N (1997) Apoptosis and protein expression after focal cerebral ischemia in rat. Brain Res 765:301-312.
37. Leker RR, Aharonowiz M, Greig NH, Ovadia H (2004) The role of p53-induced apoptosis in cerebral ischemia: Effects of the p53 inhibitor pifithrin alpha. Exp Neurol 187:478-486.
38. Bertilsson G, et al. (2008) Peptide hormone exendin-4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of Parkinson's disease. J Neurosci Res 86:326-338.
39. Harkavyi A, et al. (2008) Glucagon-like peptide 1 receptor stimulation reverses key deficits in distinct rodent models of Parkinson's disease. J Neuroinflam 21:5-19.
40. Sandyk R (1993) The relationship between diabetes mellitus and Parkinson's disease. Int J Neurosci 69:125-130.
41. Tweedie D, et al. (2007) Apoptotic and behavioral sequelae of mild brain trauma in mice. J Neurosci Res 85:805-815.
42. Montrose-Rafizadeh CC, et al. (1999) Pancreatic glucagon-like peptide-1 receptor couples positively to multiple G proteins and activates mitogen-activated protein kinase pathways in Chinese hamster ovary cells. Endocrinology 140:1132-1134.
43. Tomac AC, et al. (2002) Effects of cerebral ischemia in mice deficient in Persephin. Proc Natl Acad Sci U S A 99:9521-9526.
44. Fernagut PO, et al. (2002) Subacute systemic 3-nitropropionic acid intoxication induces a distinct motor disorder in adult C57Bl/6 mice: Behavioural and histopathological characterisation. Neuroscience 114:1005-1017.
45. Matsuura K, Kabuto H, Makino H, Ogawa N (1997) Pole test is a useful method for evaluating the mouse movement disorder caused by striatal dopamine depletion. J Neurosci Methods 73:45-48.